Being able to offer innovative treatment options and thus improve the health and live of our patients is the engine that drives us. For this reason, research and development (R&D) is not only important to Chiesi as a company with a technological focus but it is also essential to us as a manufacturer of pharmaceuticals. The path from an idea to a custom treatment with an innovative medication is very long and often difficult. The processes used to identify suitable candidates for active substances and to develop market-ready pharmaceuticals are exceptionally complex. This is why our R&D team has an interdisciplinary structure and forms a key part of our company.
The team is divided into integrated functional areas, including preclinical discovery and clinical research, chemical production and control, drug delivery technologies, regulatory affairs, pharmacovigilance, intellectual property, quality and management of R&D portfolio projects.
Our new Research and Development Centre is located in Parma, Italy. In an area of 22.000 square meters, a total of 361 employees work on new active substances and monitor clinical and preclinical studies. Along with the site in Parma, we have R&D divisions in Paris (France), Chippenham (Great Britain), Cary (US), Lidingo (Sweden), and Hillerod (Denmark).
Chiesi invests 15–20% of the total turnover of the Chiesi Group every year into research and development. This pays off: 75% of our turnover is generated by our own products.
Along with the core business in the therapeutic areas respiratory and neonatology, Chiesi also focuses on rare diseases, transplantation, gene therapy and biotechnology.